Multi-Drug 1–14 Drugs Test Panel

A Multi-Drug Test Panel is a rapid screening device that checks a urine specimen for multiple drug classes or metabolites at the same time. Instead of using separate single-drug tests, a multi-panel format allows users to screen several substances through one test device. This type of urine drug test panel is useful where broad screening is required. It can help organizations and healthcare professionals quickly identify possible drug exposure and decide whether confirmatory testing is needed.

• The Multi-Drug 1–14 Drugs Test Panel is important because drug screening needs can differ across industries, healthcare settings, and countries.
• Some users need a simple 1-panel or 3-panel test, while others require a broader 10-panel, 12-panel, or 14-panel drug test.
• Drug testing may be used in clinical practice, chronic pain evaluation, substance-use-disorder management, workplace safety programs, rehabilitation monitoring, forensic screening, and institutional compliance workflows.

The Multi-Drug 1–14 Drugs Test Panel by LARKSOIS Pharma may be used in professional diagnostic and institutional screening environments.

Applications

• Workplace and pre-employment drug screening
• Rehabilitation and de-addiction centers
• Hospitals and clinical toxicology departments
• Educational and institutional screening programs where legally permitted
• Forensic and compliance screening support
• Correctional and law-enforcement screening support
• International diagnostic distribution
• Laboratory and professional screening workflows

• The Multi-Drug Urine Test Panel generally works through a rapid chromatographic immunoassay principle. Immunoassays use antibodies directed at target analytes and are commonly used because they provide rapid turnaround and practical screening performance.
• A urine specimen is collected in a clean container. The test panel is then dipped into the urine sample or used according to the package insert.
• For official decisions, any preliminary positive or non-negative result should be confirmed using a more specific laboratory method such as GC-MS or LC-MS/MS.

The Multi-Drug 1–14 Drugs Test Panel uses a rapid urine screening method for qualitative detection of selected drugs or drug metabolites. It is designed to provide preliminary screening results according to the panel configuration and stated cut-off levels.

Benefits

• Screens 1 to 14 drug markers depending on panel configuration
• Urine-based rapid testing format
• Suitable for professional drug of abuse screening
• Helps reduce the need for multiple single-drug tests
• Easy-to-use panel design
• Suitable for laboratories, workplaces, and rehabilitation centers
• Supports international diagnostic supply requirements
• Provides fast preliminary screening results

The Multi-Drug 1–14 Drugs Test Panel is designed for urine specimens. Urine is widely used in drug screening because it is practical, non-invasive, and suitable for professional toxicology screening workflows.

Guidance

• Use urine specimens only
• Use a fresh urine specimen when possible
• Use clean sample collection procedures
• Allow test device and sample to reach room temperature if required
• Follow the product insert exactly
• Read results within the recommended time window
• Use proper labeling and documentation
• Confirm important results through a certified laboratory

Note

A rapid screening result should be considered preliminary unless confirmed by a validated laboratory method where required.

Instructions

• Amphetamine
• Methamphetamine
• Cocaine
• Marijuana / THC
• Morphine / Opiates
• Benzodiazepines
• Barbiturates
• Methadone
• Buprenorphine
• Oxycodone
• Tramadol
• MDMA
• Ketamine
• Phencyclidine

Note

Actual panel combinations, abbreviations, and cut-off levels should always be checked on the product label, technical insert, and regulatory documentation.

The Multi-Drug Test Panel provides only a preliminary qualitative result. It does not show exact drug concentration, level of impairment, route of administration, or timing of drug use.

Instructions

• False positives or false negatives may occur
• Incorrect specimen handling may affect results
• Adulterated or diluted urine samples may affect interpretation
• Testing outside the proper time window may affect results
• Medication or metabolite cross-reactivity may occur
• Drug levels below the cut-off concentration may produce negative results
• For employment, legal, medical, or forensic use, confirmatory laboratory testing and professional interpretation are recommended

Instructions

• Screens 1 to 14 drug markers depending on panel configuration
• Urine-based rapid testing format
• Suitable for professional drug of abuse screening
• Helps reduce the need for multiple single-drug tests
• Easy-to-use panel design
• Suitable for laboratories, workplaces, and rehabilitation centers
• Supports international diagnostic supply requirements
• Provides fast preliminary screening results

Note

The Multi-Drug 1–14 Drugs Test Panel by LARKSOIS Pharma is designed for professional users who need a practical, scalable, and efficient drug of abuse rapid test solution.

Steps

• Bring the test panel and urine specimen to the recommended testing condition
• Open the sealed pouch only when ready to test
• Collect urine using a clean sample collection procedure
• Dip or apply the urine specimen according to the product insert
• Wait for the test reaction to complete within the instructed time
• Read each panel result within the approved interpretation window
• Dispose of used materials according to laboratory safety rules

Note

The exact procedure must follow the official LARKSOIS Pharma product insert supplied with the Multi-Drug 1–14 Drugs Test Panel.

Positive

A positive or non-negative result suggests that one or more selected drugs or metabolites may be present in the urine specimen at or above the stated cut-off. Positive results are preliminary and should be confirmed using a recognized laboratory method where required.

Negative

A negative result suggests that the selected drug or metabolite was not detected or was below the test cut-off at the time of testing. A negative result does not always rule out exposure if sample quality, collection timing, or detection window affects the result.

Invalid

If the valid control indicator does not appear for any test strip or panel, that result is invalid. Testing should be repeated with a new device and fresh urine specimen according to the product insert.

Instructions

• Store according to the product label and package insert
• Keep the test sealed until use
• Protect from moisture
• Avoid direct sunlight
• Do not use expired or damaged devices
• Read results within the recommended time window
• Follow the temperature range mentioned on the product label

Instructions

• For professional screening use only
• Use urine specimen only as directed
• Do not reuse the test panel
• Follow the product insert carefully
• Handle all urine specimens as potentially infectious material
• Do not interpret results after the recommended reading time
• Confirm presumptive positive results with laboratory testing
• Follow applicable drug testing laws and reporting requirements

LARKSOIS Pharma provides internationally focused pharmaceutical and diagnostic products for professional healthcare and screening markets. The Multi-Drug 1–14 Drugs Test Panel is suitable for diagnostic distributors, hospitals, rehabilitation centers, workplace testing providers, toxicology laboratories, and global healthcare suppliers.

Advantages

• International diagnostic product focus
• Reliable rapid testing solutions
• Suitable for laboratories and healthcare suppliers
• Distributor-friendly product format
• Supports drug of abuse screening programs
• Designed for practical urine screening workflows
• Quality-focused standards under LARKSOIS Pharma